Hiser, Ted S.

Dr. Alfred Server is a partner in the Technology Transactions and Licensing Practice Group. He joined the firm in 1993. Dr. Server focuses his practice on corporate partnering in the Life Sciences field.

Practice

Dr. Server has represented the firm's clients in some of the most significant and highly regarded strategic alliance transactions in the Life Sciences industry, including Incyte Corporation’s recent licensing deals with Novartis and Eli Lilly and Company relating to the development and commercialization of drug candidates for the treatment of cancer and inflammation, totaling up to $2 billion in potential payments; TransTech Pharma's recent agreement with Forest Laboratories relating to a novel class of glucose-lowering agents for the treatment of diabetes and valued at up to $1.105 billion and its agreement with Pfizer, Inc. relating to the development and commercialization of drug candidates for the treatment of Alzheimer's disease; Millennium Pharmaceuticals' $500 million marketing deal for Velcade (bortezomib), a proteasome inhibitor for multiple myeloma with Ortho Biotech Products, LP, a Johnson & Johnson company; and Idenix Pharmaceuticals' agreement with Novartis Pharma AG, focused on viral drugs for hepatitis and valued at up to $862 million.

Dr. Server was involved in the establishment of The SNP Consortium, a novel, nonprofit consortium made up of 10 of the world's leading pharmaceutical companies and a British charity. The consortium was established to identify and develop a map of genetic variation in the human genome, which has been made publicly available.

Dr. Server has also advised British nonprofit organization GALVmed (the Global Alliance for Livestock Veterinary Medicines) in setting up a manufacturing and distribution chain for a vaccine that can save the lives of cattle relied upon for food and economic security by farmers and herders in Tanzania. He was recognized at an event in the city of Arusha celebrating the successful registration of the vaccine with the Tanzanian government.

Companies for whom Dr. Server has worked include: Millennium Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Wyeth; Becton, Dickinson & Company; Novartis Pharmaceuticals; Incyte Corporation; MethylGene, Inc.; Idenix Pharmaceuticals, Inc.; TransTech Pharma, Inc.; Altus Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc. and Transkaryotic Therapies Inc. (TKT).

Dr. Server received a JD degree from Harvard Law School. He received an AB degree, summa cum laude, from Princeton University, where he was elected to Phi Beta Kappa. His biomedical training includes an MD degree and a PhD degree (neurological sciences) from Stanford University, a medical internship at Peter Bent Brigham Hospital (a Harvard teaching hospital and predecessor of Brigham and Women’s Hospital), a neurology residency at Johns Hopkins Hospital, and post-doctoral fellowships in neurovirology and molecular biology at Johns Hopkins University and Harvard University. Prior to joining the firm, Dr. Server was a founder and the research director of a biotechnology company.

Honors and Awards

• Listed as a "Leading Lawyer" in the area of Intellectual property: Patent licensing in the 2009 and 2011 editions of The Legal 500 United States
• Recognized as a national leader in the life sciences: corporate/commercial field in the 2011, 2010 and 2009 editions of Chambers USA: America's Leading Lawyers in Business
• Recognized as one of the world's leading life sciences lawyers in the 2008 and 2010 editions of Who's Who Legal: The International Who's Who of Life Sciences Lawyers
• Consistently ranked in the PLC Cross-border Life Sciences Handbook as a "leading" lawyer in the Life Sciences Commercial and Corporate Partnering category for the United States. Dr. Server is one of only two lawyers in the US to receive the handbook's highest ranking in the Life Sciences Corporate Partnering practice area since 2001.
• Recognized as one of seven "star" lawyers of the firm in the PLC Which Lawyer? Yearbook 2007
• Recognized in the November 2005 edition of Boston Magazine as a "Massachusetts Super Lawyer" in business/corporate law

Speaking Engagements

• Biotechnology Industry Organization Annual International Convention: “Post-Quanta Legal Issues and Licensing Strategies” – Moderator and Speaker – May 2010
• 9^th Annual WilmerHale Intellectual Property Conference: "Post-Sale Restrictions on Patented Products Following QUANTA" – Featured Speaker – June 2009 
• The Stanford Law School Conference on Intellectual Property Law and the Biosciences: "Licensing after MedImmune" - Featured Speaker - May 2009
• 8^th Annual Advanced Patent Law Institute: "MedImmune and Licensing" - Featured Speaker - November 2007
• Licensing Executives Society Meeting – Boston Chapter: “MedImmune v. Genentech: Implications for Patent Licensing – Featured Speaker – September 2007
• 7^th Annual WilmerHale Intellectual Property Conference: “Licensing Implications of MedImmune – Featured Speaker – May 2007
• Biotechnology Industry Organization Annual International Convention: “Patent Misuse: What a Licensing Professional Needs to Know” – Moderator and Speaker - May 2007
• The Stanford Law School Conference on Intellectual Property Law and Biosciences: "Reach-Through Claims and Reach-Through Royalties: The Evolving Legal Landscape Relating to Reach-Through Rights" – Moderator and Speaker – September 2006
• Biotechnology Industry Organization Annual International Convention: "Licensing Research Tools: What's the Point?" – Moderator and Speaker – April 2006
• Biotechnology Industry Organization Annual International Convention: "Technology Licensing and the New EU Competition Rules" – Moderator and Speaker – June 2005